Haemophilia affects approximately 400,000 people worldwide
Approximately 400,000 people worldwide are living with the burden of haemophilia1
Of these, 80%-85% of people suffer with haemophilia A and require replacement Factor VIII to treat or prevent bleeding1
Approximately 15%-20% will develop antibodies (inhibitors) to the factor therapy used to treat or prevent bleeding episodes — one of the most serious complications of haemophilia2
The remainder suffer with haemophilia B and require replacement Factor IX to treat or prevent bleeding1
1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47. 2. Centers for Disease Control and Prevention (CDC). Hemophilia: inhibitors. Available at: http://www.cdc.gov/ncbddd/hemophilia/inhibitors.html. 3. Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014;20:1-5. 4. Funk MB, Schmidt H, Becker S, et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia. 2002;8:98-103. 5. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost. 2010;8:1895-1902. 6. Soucie JM, Cianfrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood. 2004;103:2467-2473. 7. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25-32. 8. Van den Berg HM, Fischer K, Mauser-Bunschoten EP, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol. 2001;112:561-565. 9. Gringeri A, von Mackensen S, Auerswald G, et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia. 2004;10 (Suppl 1):26-33. 10. Hassan TH, Badr MA, Fattah NR, Badawy SM. Assessment of musculoskeletal function and mood in haemophilia A adolescents: a cross-sectional study. Haemophilia. 2011;17:683-688. 11. Poon JL, Doctor JN, Nichol MB. Longitudinal changes in health-related quality of life for chronic diseases: an example in Hemophilia A. J Gen Intern Med. 2014;29 Suppl 3:S760-766. 12. Aledort LM, Haschmeyer RH, Pettersson H and the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236:391-399. 13. Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;1-9. 14. Shapiro AD, Donfield SM, Lynn HS, et al and the Academic Achievement in Children with Hemophilia Study Group. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics. 2001;108(6):E105. 15. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544. 16. Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11:1119-1127. 17. Noone D, O'Mahony B, Van Dijk K, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35 year old men with severe haemophilia in six countries. Haemophilia. 2013;19:44-50. 18. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol. 1996;92:973-978. 19. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM and the ESPRIT study group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9:700-710. 20. Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management [published correction appears in J Thromb Haemost. 2012;10(6):1204]. J Thromb Haemost. 2012;10(3):359-367. 21. Valentino LA, Reyes CM, Ewenstein B, et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia. 2014:20:630-638. 22. Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia. 2002;8:44-50. 23. Collins PW. Personalized prophylaxis. Haemophilia. 2012;18
(Suppl 4):131-135. 24. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167. 25. Berntorp E, Spotts G, Patrone L, Ewenstein BM. Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics. 2014 Apr 5;8:115-127. 26. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1452-1459. 27. Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269-275. 28. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med. 1997;241:395-400. 29. White GC, et al. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560. 30. Kraft J, Blanchette V, Babyn P, et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost. 2012;10:2494-2502. 31. Hilliard P, Zourikian N, Blanchette V, et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost. 2013;11:460-466. 32. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges. Semin Thromb Hemost. 2012;38:79-94.